Qiao Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qiao Zhang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Aditya Bele
2 shared publications- Adrian T. Grzybowski
Department of Molecular Genetics and Cell Biology, The University of Chicago, Chicago, Illinois
2 shared publications - Alberto Riva
Interdisciplinary Center of Biotechnology Research, University of Florida, Gainesville, USA
2 shared publications - Alexander Jackson Ruthenburg
University of Chicago
2 shared publications - Behnam Nabet
Human Biology Division, Fred Hutchinson Cancer Center, Seattle, USA
2 shared publications - Christine Will
AbbVie Inc 1 N. Waukegan Rd. North Chicago Illinois
2 shared publications
Latest Publications
- 16 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (807) , eadr3963
S100A8/A9 perturbation in bone marrow blunts antitumor immunity by promoting protumorigenic myelopoiesis in mouse models
S100A8/A9 plays a critical role in the formation of an immunosuppressive tumor microenvironment. Therefore, it is important to identify inhibitors targeting S100A8/A9 to enhance antitumor immunity. However, systemic targeting of S100A8/A9 in clinical trials has shown minimal effects. Understanding the reasons underlying this underperformance is important for developing drugs targeting S100A8/A9 that could effectively reverse the immunosuppressive tumor microenvironment. In this study, using hematopoietic system–specific conditional knockout mice in heterotopic models of lung and colon cancer and systemic pharmacological interference, we demonstrated that S100A8/A9 perturbation in the hematopoietic system accelerates tumor progression by attenuating T cell–mediated antitumor immunity. Mechanistically, S100A8/A9 perturbation triggered myeloid-biased differentiation in the bone marrow by promoting the production of abnormal granulocyte-monocyte progenitors. The local release of S100A8/A9 inhibitors using a tumor-targeted drug delivery system exhibited antitumor potential by avoiding myelopoiesis-promoting effects. These findings reveal a mechanism underlying the limited efficacy of systemic S100A8/A9 inhibition and propose a targeted strategy to enhance antitumor effects.
- 16 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (807) , eadr3963
S100A8/A9 perturbation in bone marrow blunts antitumor immunity by promoting protumorigenic myelopoiesis in mouse models
S100A8/A9 plays a critical role in the formation of an immunosuppressive tumor microenvironment. Therefore, it is important to identify inhibitors targeting S100A8/A9 to enhance antitumor immunity. However, systemic targeting of S100A8/A9 in clinical trials has shown minimal effects. Understanding the reasons underlying this underperformance is important for developing drugs targeting S100A8/A9 that could effectively reverse the immunosuppressive tumor microenvironment. In this study, using hematopoietic system–specific conditional knockout mice in heterotopic models of lung and colon cancer and systemic pharmacological interference, we demonstrated that S100A8/A9 perturbation in the hematopoietic system accelerates tumor progression by attenuating T cell–mediated antitumor immunity. Mechanistically, S100A8/A9 perturbation triggered myeloid-biased differentiation in the bone marrow by promoting the production of abnormal granulocyte-monocyte progenitors. The local release of S100A8/A9 inhibitors using a tumor-targeted drug delivery system exhibited antitumor potential by avoiding myelopoiesis-promoting effects. These findings reveal a mechanism underlying the limited efficacy of systemic S100A8/A9 inhibition and propose a targeted strategy to enhance antitumor effects.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Text and Figures from A Mutation in Histone H2B Represents a New Class of Oncogenic Driver
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Text and Figures from A Mutation in Histone H2B Represents a New Class of Oncogenic Driver
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4: H4 from A Mutation in Histone H2B Represents a New Class of Oncogenic Driver
List of all H4 missense mutations in cBioPortal nad dbSNP analysis
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4: H4 from A Mutation in Histone H2B Represents a New Class of Oncogenic Driver
List of all H4 missense mutations in cBioPortal nad dbSNP analysis